Abcuro, Inc.
Clinical trials sponsored by Abcuro, Inc., explained in plain language.
-
New hope for rare leukemia: ABC008 drug trial shows promise
Disease control CompletedThis study tested a new drug called ABC008 in 21 adults with a rare type of blood cancer called T-cell large granular lymphocytic leukemia (T-LGLL). The goal was to check the drug's safety and how it affects blood counts. Participants received increasing doses of the drug to find…
Phase: PHASE1, PHASE2 • Sponsor: Abcuro, Inc. • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New drug shows promise for rare muscle disease
Disease control CompletedThis study tested a new drug, ABC008, in 272 adults with inclusion body myositis, a rare muscle-weakening disease. The goal was to see if the drug is safe and can slow the disease's progression. Participants received either the drug or a placebo, and researchers measured muscle f…
Phase: PHASE2, PHASE3 • Sponsor: Abcuro, Inc. • Aim: Disease control
Last updated May 19, 2026 11:48 UTC